BioNexus Gene Lab annual ebitda
2018
2019
BioNexus Gene Lab EBITDA Growth & History (BGLC)
BioNexus Gene Lab's calculated EBITDA was −$233,991 for fiscal 2019.
View full BioNexus Gene Lab company overviewBioNexus Gene Lab annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2019 | 2019-12-31 | −$233,991 | −$334,503 | — |
| 2018 | 2018-12-31 | $100,512 | — | — |
BioNexus Gene Lab quarterly ebitda
Q3.18
Q3.19
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2019 | 2019-09-30 | −$39,797 | — | — |
| Q3 2018 | 2018-09-30 | −$45,173 | — | — |
BioNexus Gene Lab ebitda trends
Across the available reported history, BioNexus Gene Lab's ebitda decreased from $100,512 to −$233,991, a change of −$334,503. The latest reported quarter, Q3 2019, shows −$39,797.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioNexus Gene Lab filings at SEC.gov ↗